These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 34866586)
1. The DESolve novolimus bioresorbable Scaffold: from bench to bedside. Mattesini A; Bartolini S; Sorini Dini C; Valente S; Parodi G; Stolcova M; Meucci F; Di Mario C J Thorac Dis; 2017 Aug; 9(Suppl 9):S950-S958. PubMed ID: 28894601 [TBL] [Abstract][Full Text] [Related]
2. Fully bioresorbable drug-eluting coronary scaffolds: A review. Charpentier E; Barna A; Guillevin L; Juliard JM Arch Cardiovasc Dis; 2015; 108(6-7):385-97. PubMed ID: 26113479 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of long segment coronary artery lesions overlapped with novolimus-eluting DESolve scaffold: Disappointment or futuristic? İbişoğlu E; Çakal S; Çakal B; Güneş HM; Boyraz B; Boztosun B Anatol J Cardiol; 2021 Dec; 25(12):912-919. PubMed ID: 34866586 [TBL] [Abstract][Full Text] [Related]
4. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155 [TBL] [Abstract][Full Text] [Related]
5. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932 [TBL] [Abstract][Full Text] [Related]
7. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164 [TBL] [Abstract][Full Text] [Related]
8. The DESolve Demola P; Meucci F; Stolcova M; Mario CD; Mattesini A Future Cardiol; 2021 Sep; 17(6):945-951. PubMed ID: 33507091 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice. Cakal B; Cakal S; Karaca O; Omaygenc MO; Yilmaz FK; Gunes HM; Ozcan OU; Ibisoglu E; Boztosun B Minerva Cardiol Angiol; 2021 Jun; 69(3):261-268. PubMed ID: 32326676 [TBL] [Abstract][Full Text] [Related]
10. Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. Pereira GTR; La Manna A; Ichibori Y; Vergara-Martel A; Ramos Nascimento B; Samdani AJ; Capodanno D; D'Agosta G; Gravina G; Venuti G; Tamburino C; F Attizzani G Int J Cardiovasc Imaging; 2019 Oct; 35(10):1767-1776. PubMed ID: 31175527 [TBL] [Abstract][Full Text] [Related]
11. Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions. Verheye S; Costa RA; Schofer J; Ormiston JA; Maeng M; Dudek D; Skurk C; Botelho RV; Costa JR; Chamié D; Abizaid AS; Boersma E; Abizaid AA EuroIntervention; 2019 Oct; 15(8):685-687. PubMed ID: 30530403 [No Abstract] [Full Text] [Related]